VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Technical Scanner
RSI, Moving averages & volume momentum signals
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
Minervini — VCPContraction bases in Stage 2 uptrends
Minervini — Trend TemplateFull 8-rule Stage 2 screen
O'Neil — Cup with HandleBase breakouts with RS leadership
O'Neil — CANSLIM LeadersGrowth leaders with RS ≥ 85
Qullamaggie — High Tight FlagsPower plays after a large advance
Qullamaggie — Momentum Leaders1/3/6-month strength leaders
Livermore — Pivotal PointsMulti-touch resistance breakouts
View All Playbooks...
Breakouts
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
Breakouts
WatchlistPricing
Ctrl K
Pricing
BDX
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsCompareWatchlist
BDXBecton, Dickinson and Company
$183.00$50.4B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
BDX logo

Becton, Dickinson and Company

BDX
NYSE · Medical Instruments
$183.00
At close - Sep 22, 4:00 PM EDT - USD
Market Cap$50.42B
P/E31.4x
52W High$193.07
Volume1.37M
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q3

Deleveraging and Buybacks Offset Revenue Contraction

BDX is navigating a portfolio transition marked by the Embecta spin-off, which drove a 9.5% YoY revenue decline in 2026Q3, yet gross margin resilience at 46.5% and cumulative operating cash flow of $8.5B versus net income of $3.5B suggest underlying cash gener...

GrowthMixed
ProfitabilityStable
ValuationExpensive
TechnicalsHealthy
Explore valuation models
MARKET ACTION

BDX price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

11/12 Beats

EPS beat 11 of last 12 quarters

02

Valuation risk

In Line

P/E is in line with peer median

03

Market leadership

RS 78 · Avg

Average momentum (RS Rating: 78)

04

Healthy Uptrend

Uptrend

Price > 50DMA > 200DMA

Next CatalystConfirmed earnings · Nov 5
01

Build the investment case

Start with the evidence for owning the stock and the risks that can break the thesis.

EXECUTIVE THESIS

The Investment Case

Full Analysis
Fundamental Trajectory

Revenue contracted 9.5% YoY in 2026Q3 to $5.0B, yet gross margin expanded to 46.5% from 45.7% sequentially, indicating pricing power and mix benefits despite volume declines.

Analyst Consensus+2.1% target
Hold(34 analysts)
16 Buy17 Hold1 Sell

The Bull Case

Upside Catalysts

Attractive valuation metrics

BDX's forward P/E ratio of 12.82-13.44 suggests potential undervaluation compared to its trailing P/E of 34.55-35.03, indicating earnings growth expectations.

Strong institutional interest

Multiple bullish theses from reputable sources like MoneyShow and Value Don't Lie highlight institutional confidence in BDX's growth prospects.

Leadership stability

Appointment of long-time executive Vitor Roque as CFO demonstrates continuity in leadership and strategic execution.

The Bear Case

Key Downside Risks

Market performance

Price History →

Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
BDX+21.47%
S&P 500 (^GSPC)+13.20%
1-Year Return
BDX+62.18%
S&P 500 (^GSPC)+15.98%
3-Year Return
BDX+18.15%
S&P 500 (^GSPC)+81.45%
5-Year Return
BDX+28.75%
S&P 500 (^GSPC)+79.99%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E5Y High
31.4x
Forward P/EExpansion
14.4x
EV/EBITDA80th %ile
13.6x
FCF YieldCash Flow
5.3%

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
31.4x
23.4x
80th· High
EV/EBITDA
13.6x
13.2x
80th· High
Price/FCF
18.9x
14.1x
60th· Fair
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
Bear$155.88-14.8%
Base (Fair)$313.28+73.1%
Bull$527.44+188.2%
$155.88 Bear$313.28 Base$527.44 Bull
Current Market Price: $183.00
Trades at a 41.6% discount to Base DCF ($313.28)
Open DCF & Valuation Models →Chart Terminal ↗

Growth & profitability

Annual revenue & EPS trend
Revenue
$21.84B+8.2% YoY
Net income
$1.68B-1.6% YoY
Free cash flow
$2.67B-13.1% YoY
Operating margin
11.8%-0.1 pts YoY
ROIC (TTM)4.3%
Avg ROIC 5Y-
ROE (TTM)6.5%
Piotroski Score7 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate11/12 (92%)
Revenue Beat Rate7/12 (58%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q3 2026Latest
Aug 6, 2026
$3.23+2.9%
vs $3.14
$5.0B+2.0%
vs $4.9B
Q2 2026
May 7, 2026
$2.90+4.3%
vs $2.78
$4.7B+0.9%
vs $4.7B
Q1 2026
Feb 9, 2026
$2.91+31.7%
vs $2.21
$4.5B-12.8%
vs $5.1B
Q4 2025
Nov 6, 2025
$3.96+1.0%
vs $3.92
$5.9B-0.3%
vs $5.9B
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

5 Stories
Seeking Alpha·5d ago
The Dividend Kings Ranked By Quality Scores (September 2026)

Dividend Kings have a 50+ year track record of increasing dividends, showcasing resilience through economic challenges. I rank the Dividend Kings using my 9F Quality Scores, blending qualitative and quantitative factors for a robust, investment-grade assessment. ADP stands out as the best total-return candidate. It is undervalued, high-quality, and offering a strong projected dividend growth rate and Adjusted Chowder Number.

Defense World·6d ago
Corient Private Wealth LP Decreases Stake in Becton, Dickinson and Company $BDX

Corient Private Wealth LP lessened its position in shares of Becton, Dickinson and Company (NYSE: BDX) by 9.4% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 70,198 shares of the medical instruments supplier's stock after selling 7,308 shares during the period.

Zacks Investment Research·Sep 15, 2026
BDX Deploys Vmax 160 to Advance Intelligent Pharmacy Automation

BD expands U.S. pharmacy automation with Vmax 160 at Fairview to handle complex specialty and refrigerated medications.

PRNewsWire·Sep 14, 2026
BD Advances Intelligent Robotics to Transform the Future of Pharmacy Care at Fairview

First-of-its-kind U.S. deployment of BD Vmax 160 expands pharmacy automation beyond traditional dispensing, helping health systems manage growing demand for specialty therapies, refrigerated medications, and increasingly complex fulfilment needs FRANKLIN LAKES, N.J., Sept. 14, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Fairview Health Services has become the first health system in the United States to deploy the BD Vmax 160, a next generation pharmacy automation robot designed to help health systems manage the increasing complexity of specialty therapies and refrigerated medicines in high-volume, centralized outpatient pharmacy operations.

Filtered for Becton, Dickinson and CompanyMore Headlines
04

Compare before deciding

Benchmark BDX against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Becton, Dickinson and Company (BDX)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
BDX logoBDXBecton, Dickinson and CompanyCurrent
$183.00$50.42B31.398.23%7.68%6.54%2.28%
BAX logoBAXBaxter International Inc.
$23.68$12.23B-13.535.72%-9.27%-16.67%—
BSX logoBSXBoston Scientific Corporation
$44.92$66.77B23.1519.87%17.47%14.76%—
MDT logoMDTMedtronic plc
$90.77$116.54B24.348.43%13.93%10.51%—
SYK logoSYKStryker Corporation
$275.07$105.45B32.7511.16%14.43%16.36%—
ZBH logoZBHZimmer Biomet Holdings, Inc.
$93.98$18.18B26.477.2%9.48%6.36%—

Compare BDX vs Peers

Becton, Dickinson and Company (BDX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs BAX

Most directly comparable listed peer for BDX.

Scale Benchmark

vs TMO

Larger-name benchmark to compare BDX against a more recognizable public peer.

Peer Set

Compare Top 5

vs BAX, BSX, MDT, SYK

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

BDX SEC Filings & Documents

Becton, Dickinson and Company (BDX) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Aug 6, 2026·SEC

Material company update

Jul 22, 2026·SEC

Material company update

May 29, 2026·SEC

10-K Annual Reports

2
FY 2025

Nov 25, 2025·SEC

FY 2024

Nov 27, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Aug 6, 2026·SEC

FY 2026

May 7, 2026·SEC

FY 2026

Feb 9, 2026·SEC

Get notified when BDX posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

BDX Frequently Asked Questions

Becton, Dickinson and Company (BDX) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Becton, Dickinson and Company's revenue?

Becton, Dickinson and Company (BDX) reported $20.84B in revenue for fiscal year 2025. This represents a 652% increase from $2.77B in 1996.

How fast is Becton, Dickinson and Company growing?

Becton, Dickinson and Company (BDX) grew revenue by 8.2% over the past year. This is steady growth.

Is BDX profitable?

Yes, Becton, Dickinson and Company (BDX) is profitable, generating $941.0M in net income for fiscal year 2025 (7.7% net margin).

Dividend & Returns
Does BDX pay dividends?

Yes, Becton, Dickinson and Company (BDX) pays a dividend with a yield of 2.28%. This makes it attractive for income-focused investors.

What is BDX's return on equity?

Becton, Dickinson and Company (BDX) has a return on equity (ROE) of 6.5%. This is below average, suggesting room for improvement.

What is Becton, Dickinson and Company's free cash flow?

Becton, Dickinson and Company (BDX) generated $2.61B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

What if you invested $1,000 in BDX back in 1996?

Total return calculator · dividends reinvested · 30+ years of data

See returns →